Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 774

1.
2.

Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study.

Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S.

Anticancer Drugs. 2002 Apr;13(4):417-24.

PMID:
11984088
3.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD.

J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46.

PMID:
14679153
5.
6.

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM.

Eur J Cancer. 1998 Oct;34(11):1693-700.

PMID:
9893654
7.

[Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].

Li HP, Ma LW, Zhang SL, Jia TZ, Deng HJ, Zhang ZH, Liang L, Wang MP, Xiao Y, Cao BS, Chen S, Wang YF.

Zhonghua Zhong Liu Za Zhi. 2006 Nov;28(11):848-51. Chinese.

PMID:
17416008
8.

Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.

Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL.

J Clin Oncol. 2006 Nov 1;24(31):4956-62.

PMID:
17075113
9.

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).

Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K; TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).

Anticancer Res. 2002 Jul-Aug;22(4):2325-32.

PMID:
12174922
10.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N.

J Natl Cancer Inst. 2001 Jan 17;93(2):112-20.

PMID:
11208880
11.

Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.

Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K.

J Clin Oncol. 2007 Jun 20;25(18):2509-15.

PMID:
17577027
12.
13.

Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.

Adjuvant Breast Cancer Trials Collaborative Group.

J Natl Cancer Inst. 2007 Apr 4;99(7):506-15.

PMID:
17405995
14.

Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.

Mikhak B, Zahurak M, Abeloff MD, Fetting JH, Davidson NE, Donehower RC, Waterfield W, Kennedy MJ.

Cancer. 1999 Feb 15;85(4):899-904.

PMID:
10091768
15.
16.
17.

The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.

Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA.

Cancer. 1998 Oct 15;83(8):1529-39.

PMID:
9781946
18.

Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers.

Schwartzberg LS, Birch R, West WH, Tauer KW, Wittlin F, Leff R, Campos L, Rymer W, Carter P, Mangum M, Greco FA, Hainsworth J, Raefsky E, Blanco R, Buckner CD, Weaver CH.

Am J Clin Oncol. 1998 Oct;21(5):523-31.

PMID:
9781614
19.

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.

Stemmer SM, Hardan I, Raz H, Adamou AK, Inbar M, Gottfried M, Merrick Y, Cohen Y, Sulkes A, Ben-Baruch N, Pfeffer RP, Brenner HJ, Rizel S.

Bone Marrow Transplant. 2003 Apr;31(8):655-61.

PMID:
12692605
20.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.

J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27.

PMID:
16505417

Supplemental Content

Support Center